Background
==========

Nowadays, breast cancer is still characterised by high mortality: the early identification of breast pathology has always been a challenge for research studies and new devices for increasing the identifications of early-stage tumours are needed. It is well known that, in women with dense breasts, mammography is less accurate in the detection of cancer \[[@ref1]\] and screening risks to fail the identification of potentially deadly neoplasia. Over the years, the complementary use of the hand-held ultrasound (HHUS) in daily clinical practice, and in screening for some study protocols, has led to excellent results and to better detection of breast tumours \[[@ref2]--[@ref4]\]. In spite of these achievements, HHUS presents some defects that are often difficult to solve as a lack of standardisation, high level of skill non-reproducibility, small field of view (FOV) and high commitment of physician time \[[@ref3]\]. In this scenario, the invention of a new device, such as the automated breast ultrasound (ABUS), has tried to overcome this kind of problems \[[@ref5], [@ref6]\] offering a minor time of acquisition, larger FOV, high-resolution imaging, multiplanar reformations and probe designed to fit the normal curvature of the breast minimising the induced artefacts of the periphery \[[@ref7]\]. Furthermore, ABUS allows the radiologist to interpret the images in a separate time after the acquisition, optimizing the physician time.

In many studies, ABUS has proven to be an excellent, non-ionising alternative to other supplemental screening options for women with dense breast tissue \[[@ref8]--[@ref10]\]. More controversial is the possibility of using ABUS in the daily clinical practice: in this field, there are several studies that demonstrate excellent results with ABUS, especially compared with conventional HHUS, but they have been performed on a much smaller number of patients compared to those performed to evaluate the effectiveness of ABUS in screening.

The aim of this work is to revise the reliability of the ABUS in screening and daily clinical practice. Our hope is to give a new perspective in the use of the ABUS in a broader context \[[@ref11], [@ref12]\]. This new scenario would potentially offer excellent results, especially for the management of patients.

Technique
=========

The ABUS is a computer-based system for evaluating the whole breast. Each breast is imaged in three views: anteroposterior, medial, and lateral, with an automated 6--14 MHz linear array transducer attached to a rigid compression plate. This system received FDA clearance as an adjunct to screening mammography in 2008 \[[@ref13]\].

The transducer moves automatically over the breast, in a way similar to that of HHUS, acquiring transverse images in craniocaudal linear overlapping rows.

Each of the three views is acquired up to about 300 2D images and, from all of them, it is possible to get multiplanar reconstructions of the entire breast, from the skin to the chest wall: in particular, the coronal plane, also known as the 'surgical view', is essential for the review phase. In fact, the standardised review process for quick navigation involves a patented thick-slice coronal plane.

Nowadays, several types of ABUS systems are available, including two main categories: prone- and supine-scanners \[[@ref14]\].

Prone-type scanners are still under development; while supine scanners are regularly used in clinical practice.

When the examination is performed in the supine position, a towel of sponge is placed under the shoulder: this helps to spread out the breast tissue evenly, with the nipple pointing to the ceiling. A hypoallergenic lotion is placed evenly on the breast with an additional amount on the area of the nipple to allow adequate contact between the probe and the skin.

The ABUS scan is continuous and automated. During the acquisition, women are asked not to move and to breathe smoothly. Volume acquisitions are obtained in the axial plane starting from the inferior part of the breast with coronal and sagittal reconstruction. Image data automatically acquire a 15.4 cm × 17.0 cm volume from the skin to the chest wall up to 5 cm deep with a 0.2-mm thickness of each slice.

For each breast, three volumes are obtained: the central (anteroposterior) volume with the nipple in the centre of the footprint (shape of a donut), the lateral volume that included the upper outer part of the breast tissue with the nipple located in the inferior-medial corner and the medial volume that included the inner and inferior part of the breast tissue. A nipple marker is placed in every examination for accurate localisation of different quadrant of the breast.

The depth of the scan should be evaluated to ensure that the deep and the peripheral breast tissues are included in the image fields depending on the breast size: from 3.5 to 5 cm, respectively, for small, medium and large breasts. For optimal image quality, in women with larger breasts, additional views (superior and inferior) are taken to avoid the upper and deep central tissue exclusion.

Conventionally, three 1 minute scans are enough for scanning the entire breast, excluding the axilla. However, in the case of larger breasts, more than one scan may be required to cover the entire field of interest. The average total time to complete the examination is approximately 15 minutes.

Afterimage acquisition by the technicians, the data are saved and transferred to dedicated workstations where radiologists, in a separate time, can review them using both native and reconstructed scans.

Hence, ABUS increases reproducibility, reduces operator-dependence and physicians time due to the possibility to review images retrospectively, and adds new diagnostic information with multiplanar reconstructions. On the other hand, there are also some main limitations, such as the exclusion of axillary regions from the field of view and the absence of tools to assess vascularity and tissue elasticity \[[@ref14]\].

An example of the ABUS image is shown in [Figure 1](#figure1){ref-type="fig"}.

Applications
============

Screening
---------

The use of an ABUS designed for breast cancer screening was proposed by some authors \[[@ref5], [@ref6]\] already since 1980, in order to overcome the limitations of mammography. Interest in ABUS's application for screening has further grown, especially in recent years, due to increased awareness among the problem of breast \[[@ref15]\].

The application of ABUS as a complementary screening technique has been widely consolidated in the literature for women with dense breast indeed. There are some studies in the literature, concerning a large number of patients, with very numerous populations, some mono and others multicentric, which all agreed that the combined use of mammography and ABUS in screening women with dense breasts lead to an augmented sensitivity in breast cancer detection with a not significant reduction in specificity, as reported in [Table 1](#table1){ref-type="table"}.

Kelly *et al* \[[@ref8]\] published a multicentre study based on 4,419 women with dense breasts and/or at elevated risk of breast cancer, compared the diagnostic performance of mammography alone versus that of ABUS plus mammography. The results shown that the mean sensitivity increased from 50% to 81%, an improvement of 63% in the number of cancer cases identified: all the readers involved in the study found more cancers individually, and all found 16%--29% more cancers than the best mammography reader did with mammography alone. Specificity was 89.9% for ABUS, 95.15% for mammography and 98.7% for the combined modalities \[[@ref8]\]. Kelly *et al* \[[@ref16]\] have also conducted a study on radiologists' performance in detecting lesions in dense breasts using mammography alone versus automated whole breast ultrasound plus mammography: also in this case the sensitivity increased by adding ABUS, from 50% to 81%. Noteworthy, the interpretation time per ABUS was 7 minutes 58 seconds, shorter than the time reported in the ACRIN 6666 trial regarding HHUS screening (19 minutes).

Giuliano \[[@ref17]\] in a study performed in 3,418 asymptomatic women with mammographically dense breasts shows a detection of mammography plus ABUS of 12.3 per 1,000 breast cancers, compared to 4.6 per 1,000 by mammography alone.

The Somoinsight study \[[@ref7]\] in 2015, a multicentre prospective trial, including 15,318 asymptomatic women with dense breast, compared mammography versus mammography plus ABUS. As results, combined imaging approach led to an increase in cancer detection rate of 1.9 per 1,000 women with a rise in sensitivity of 26.7% and specificity of 85.4% for mammography alone versus 72% for mammography plus ABUS.

Even Wilczek *et al* \[[@ref9]\] in 2016 , in a single-centre study, evaluated 1,668 asymptomatic women, with heterogeneously dense (50%--74% dense tissue) / extremely dense (³75% dense tissue) breast parenchyma. The combination of digital mammography plus ABUS determined an increase in cancer detection of 2.4 per 1,000 women screened. The increase in sensitivity was 36.4% for combined modalities versus mammography alone at study entry, while, including interval cancers, sensitivity increased by 25%. Specificity decreased by 0.7% when ABUS was added to mammography.

Giger *et al* \[[@ref10]\], in a multi-reader study on asymptomatic women with BIRADS C or D breast density, shown an improvement in detection of both mammography-negative and mammography-positive breast cancers with the use of ABUS. The improvement in sensitivity was 23.9%, for mammography-negative breast cancers (*p* = 0.004) and 5.9% for mammography-positive breast cancers (*p* = 0.234); specificity decreased from 78.1% for mammography alone to 76.2% for the combined modalities. Combined ABUS-mammography compared to mammography alone, significantly improved reader's detection of breast cancers in women with dense breast tissue without substantially affecting its specificity.

Those results can be further improved with more radiologists' experience and confidence in the new method especially by reducing unnecessary recall \[[@ref18]\].

Indeed, the adjunct of ABUS to screening mammography increased the recall rates and doubled the recalls leading to biopsy, with a decrease in positive predictive value.

The results of screening applications of ABUS are summarised in [Table 1](#table1){ref-type="table"}.

Clinical practice
=================

ABUS, compared to HHUS, is still under examinations in different clinical aspects: detection rate and characterisation of breast lesions, diagnostic performance, sensibility and specificity, inter-observer agreement and use in the pre-operative setting or as a second look procedure.

There are several studies \[[@ref19]--[@ref22]\] although performed in relatively small numbers of patients, that demonstrate similar results in terms of sensitivity and specificity of ABUS compared to HHUS, as it is shown in [Table 2](#table2){ref-type="table"}.

Considering the studies with the largest number of patients: Wang *et al* \[[@ref19]\], in a study of 213 patients reported a sensitivity of ABUS versus HHUS of 95.6% versus 90.3% and a specificity of 80.5% versus 82.5%. Jeh *et al* \[[@ref23]\], in a study of 173 patients reported a sensitivity of 88% versus 95.7% and a specificity of 76.2% versus 49.4%.

More recently, Lin Niu *et al* \[[@ref24]\] in 2019 studied 599 breast lesions in 398 women comparing ABUS and HHUS with pathologic results or 1-year follow-up as a reference. The results shown that there was a significant difference between ABUS and HHUS in terms of sensitivity (92.23% versus 82.52%; *p* \< 0.01) but not in terms of diagnostic accuracy, specificity, positive and negative predictive value.

Also, as expected, the detection rate increases as the lesion size increases \[[@ref25]\]. Anyway, only few studies have obtained a statistically significant increase in the detection rate of ABUS compared to HHUS: those of Zhang *et al* \[[@ref26]\], Xiao *et al* \[[@ref27]\] ([Table 3](#table3){ref-type="table"}).

Even in terms of characterisation capacity of a breast lesion according to the BIRADS classification, ABUS and HHUS are similar. Examples are the studies of Golatta *et al* \[[@ref28]\], which found good agreement between ABUS and HHUS (*k* = 0.34) in assigning a BIRADS value: in particular, this agreement increases (*k* = 0,68) if you characterise a lesion by assigning it to two categories (non-suspect = BIRADS 1--2 or suspect = BIRADS 4--5). Similar results in terms of concordance of assignment of a BIRADS value were obtained in the studies of Shin *et al* \[[@ref25]\] (*k* = 0,64) and Kim *et al* \[[@ref29]\] (*k* = 0.773 ± 0.104). In Kim's study, the BIRADS descriptor that presented the best agreement was the 'orientation' (*k* = 0.608 ± 0.210) and the worst was the 'posterior echo feature' (*k* = 0.371 ± 0.225); Kotsianos-Hermle *et al* \[[@ref30]\] reported a good correlation for the descriptor 'margin'.

Consistent with the good characterisation of breast lesions, ABUS has good diagnostic performances in differentiate benign and malignant lesions without significant superiority or inferiority over HHUS, in the majority of studies \[[@ref19], [@ref20], [@ref22], [@ref30]--[@ref33]\]. However Choi *et al* \[[@ref34]\], in a study conducted in 5,566 asymptomatic women, 1,866 evaluated with ABUS and 3,700 with HHUS, demonstrated a significant difference between ABUS and HHUS, in terms of diagnostic accuracy (97.70% of ABUS versus 96.54% of HHUS; *p* = 0.022) and specificity (86.2% versus. 87.5%; *p* = 0.018); no difference in terms of sensitivity was observed (77.78% versus 62.50%; *p* \> .05). Similar data of diagnostic accuracy are observed in the study of Kim *et al* \[[@ref29]\].

More recently, Zhang *et al* \[[@ref35]\] demonstrated a better diagnostic performance of ABUS versus HHUS, in particular in the detection of precancerous lesions or cancers (BIRADS 4-5). In this hospital-based multicentre diagnostic study, Zhang *et al* \[[@ref35]\] have evaluated the clinical performance of the ABUS for breast cancer detection by comparing it to handheld ultrasound and mammography (MG) in 1973 women, from 30 to 69 years. The results not only shown a good diagnostic performance of ABUS but also that the ABUS results, compared to HHUS, were more consistent with the pathology results in the BIRADS 4--5 groups: 78.6% of women classified as BI-RADS 4--5 based on the ABUS were diagnosed with precancerous lesions or cancer, which was 7.2% higher than that of women based on HHUS. For BI-RADS 1--2, the false-negative rates of the ABUS and HHUS were almost identical and were much lower than those of MG.

Furthermore, it appears that ABUS has shown a better ability to identify calcifications and the 'retraction phenomenon', a new diagnostic information peculiar of coronal plane reconstruction, with high accuracy for malignant breast lesions: Lin *et al* \[[@ref21]\] have achieved an accuracy of 91.4%.

Vourtsis *et al* \[[@ref36]\] shown that ABUS outperform HHUS in the detection of architectural distortion as 'a retraction phenomenon sign' due to the coronal plane and can support mammography in the detection of non-calcified carcinomas in women with dense breasts.

The retraction phenomenon is defined as the convergence tendency of the tissue surrounding a lesion with or without cord-like hyperechogenicity intervals on the coronal plane. Its most important clinical application is the high specificity for breast malignancies: in malignant masses, retraction phenomenon is more commonly seen in tumours of small size, short distance to the skin and low histological grade \[[@ref36]\].

To get a significant impact of ABUS on clinical practice, a good inter-observer reliability is mandatory. The studies in the literature have tested the agreement between different readers in terms of allocation of a BIRADS category and description of the characteristics of breast lesions (such as location, size, shape, etc..): the results are heterogeneous but the agreement between readers may increase with a dichotomization of BIRADS score in two categories (non-suspect = BIRADS 1--2 or suspect = BIRADS 4--5) \[[@ref37]--[@ref39]\].

Images of comparison between ABUS, HHUS and mammography are shown in [Figures 2](#figure2){ref-type="fig"} and [3](#figure3){ref-type="fig"}.

In conclusion, the great majority of the studies using the new-generation ABUS scanners reported high sensitivity and specificity, comparable or sometimes better than HHUS and full field digital mammography (FFDM).

ABUS avoids the dependence on the sonographer and allows to standardize the examination procedure.

Surely, we have to consider some weak points: the importance of the learning curve, as limited experience with ABUS, can affect sensitivity and specificity, the inability of ABUS to evaluate the axillary region, to investigate lesion vascularization of tissue elasticity.

Artifacts
=========

The effectiveness of ABUS has been demonstrated in many studies \[[@ref19], [@ref20], [@ref22], [@ref30]--[@ref33]\], however many artifacts can reduce diagnostic appropriateness.

Corrugation is the most common artifacts: it is due to respiratory motion.

It is essential that during the examination the patient avoid to speak or to cough \[[@ref40]\].

Similarly, it is important to ensure an uniform compression and proper position of the breast and to avoid insufficient lotion application: indeed one important artifact it's the posterior shadowing that develops at the interface of fat lobules, due to the lack of previous precautions \[[@ref41]\].

Other applications
==================

Some studies have also evaluated the effectiveness of ABUS compared to HHUS in pre-operative cancer assessment. ABUS was more accurate than HHUS in assessing the extent of the disease and the mean lesion size \[[@ref12]\], the larger diameter \[[@ref42]\] and the total volume \[[@ref43]\] being essential in the preoperative field, to assess the real extension of the lesion.

Furthermore, ABUS seems to be excellent as a 'second look' tool after breast MRI (reference needed).

This can be very useful for the low specificity of MRI.

For example, in the study of Schmachtenberg \[[@ref44]\], 3D ABUS correlates well with MRI and histopathological measurements. An example of this correlation is shown in [Figure 4](#figure4){ref-type="fig"}.

Chae *et al* \[[@ref45]\] shown that on 729 MRI, 80 additional suspicious lesions in 58 patients (age range: 27--63 years, mean: 45 years) were identified by pre-operative MRI. Of the 80 suspicious lesions detected at MRI in 58 women, ABUS detected 70/80 lesions, 10% more than HHUS. Automated breast ultrasound can reliably detect additional suspicious lesions that have been identified on breast MRI being more rapid and less costly than HHUS and may help in the decision on the biopsy guidance method (HHUS versus MRI).

These data were also confirmed by Kim *et al* \[[@ref46]\] through a prospective study in which they found 76 suspicious lesions in 40 women who underwent pre-operative MRI. ABUS had significantly higher values of detection rates than HHUS (94.7% versus 86.8%; *p* \< 0.05).

Another interesting application is the possibility to correlate the imaging features obtained by an ABUS and molecular subtypes of breast cancer:

Zheng *et al* \[[@ref47]\] in a study on 303 malignant breast tumours shows a strong correlation between the "retraction phenomenon" and the molecular subtypes.

Similar results were obtained by Wang *et al* \[[@ref48]\] in a study performed on 118 lesions and by Jiang *et al* \[[@ref49]\] in a study performed on 85 patients.

Compared to HHUS, ABUS is therefore a valuable additional tool not only in screening but also in the clinical field, in the characterisation and diagnostic accuracy of breast lesions, as reported in [Figure 5](#figure5){ref-type="fig"}.

Artificial intelligence
-----------------------

For its reproducibility and way of preserving images, the ABUS lets the use of computer-aided design CAD \[50\] and techniques of artificial intelligence aimed at increasing diagnostic performance with deep machine learning: for example Block-Based Region Segmentation, can be done relatively easily with ABUS compared to conventional HHUS allowing the use of traditional machine learning models. ABUS opens promising scenarios in the field of artificial intelligence to be confirmed with other studies. Future perspectives include the integration of radiomics and deep learning in the further development of 3D ABUS \[[@ref51]\].

Indeed, Radiomic 3D ABUS signature, combinations of imaging features, could accurately differentiate between malignant and benign breast lesions \[[@ref52]\].

Conclusions
===========

The ABUS offers valuable impact in the detectability of breast lesions and the differentiation of malignant from benign lesions, with a higher inter-observer agreement. Its use, both in screening, in addition to mammography, and in clinical practice, seems to offer excellent results, not inferior to those of traditional ultrasound, with the advantage of great saving in medical time and in reducing some of the most common problems of the HHUS.

Furthermore, due to its characteristics, ABUS is particularly promising for studies involving artificial intelligence and radiomics, opening new extremely interesting study scenarios in the diagnostic field.
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![3D ultrasound image at the dedicated workstation of a 82-year-old patient with biopsy proven ductal infiltrating carcinoma. a and b: reconstructed coronal plane; the lesion is marked as a reference point. Arrowhead shows the nipple. c and d: axial plane: the lesion is marked as a reference point. Arrowhead shows the nipple.](can-14-1062fig1){#figure1}

![62-year-old patient with biopsy proven left breast carcinoma. a: Hand-held ultrasound showing the lesion (arrow). b: 3D ultrasound (ABUS) image at the dedicated workstation. Reconstructed coronal plane: the lesion is marked with the arrow; the nipple is marked with the arrowhead. c: reconstructed axial plane of Automatic Breast Ultrasound (ABUS): the lesion is marked with with the arrow; the nipple is marked with arrowhead.](can-14-1062fig2){#figure2}

![50-year-old patient with biopsy proven left breast carcinoma. a: 3D ultrasound (ABUS) image at the dedicated workstation. Reconstructed coronal plane: the lesion is marked as a reference point. The nipple is marked with the arrowhead. b: 3D ultrasound (ABUS) image at the dedicated workstation. Reconstructed axial plane: the lesion is marked as a reference point. The nipple is marked with the arrowhead. c: Full field digital mammography of the left breast in which the lesion is fairly visible.](can-14-1062fig3){#figure3}

![50-year-old patient with biopsy proven left breast carcinoma. a: 3D ultrasound (ABUS) image at the dedicated workstation. Reconstructed coronal plane: the lesion is marked as a reference point. The nipple is marked with the arrowhead. b: 3D ultrasound (ABUS) image at the dedicated workstation. Reconstructed axial plane: the lesion is marked as a reference point. c: Breast MRI: the lesion is marked with the arrow.](can-14-1062fig4){#figure4}

![30-year-old patient with right breast carcinoma: a and b: 3D ultrasound (ABUS) image at the dedicated workstation. Reconstructed sagittal plane: the lesion is marked as a reference point. The nipple is marked with the arrow. c and d: 3D ultrasound (ABUS) image at the dedicated workstation. Reconstructed axial plane: the lesion is marked as a reference point.](can-14-1062fig5){#figure5}

###### Value of sensibility, specificity and detection rate of Full Field digital Mammography and Full field digital Mammography plus Automatic Breast Ultrasound in screening programme.

  Author                                     Year   Nb of pt   Sensibility %   Specificity %   Detection rate per 1,000                
  ------------------------------------------ ------ ---------- --------------- --------------- -------------------------- ------ ----- ------
  Kelly *et al* \[[@ref16]\]                 2010   4419       40              81              95.15                      98.7   2,6   6,5
  Giuliano *et al* \[[@ref17]\]              2012   3418       76,00           96.7            99.70                      98.2   4,6   12,3
  Brem (The Somoinsight Study) \[[@ref7]\]   2014   15318      73.2            100             85.4                       72     5,4   7,3
  Wilczek *et al* \[[@ref9]\]                2016   1668       63.6            100             99                         98.4   4,2   6,6
  Giger *et al* \[[@ref10]\]                 2016   185        57.5            74.1            78.1                       76.2   //    //

FFDM: Full field digital mammography.

ABUS: Automatic breast ultrasound.

Nb of pt: number of patients.

###### Comparison of sensibility and specificity of ABUS (Automatic Breast Ultrasound) and US (Hand Held Ultrasound) in daily clinical practice.

  Author                                  Year   Number of patients   Sensibility %   Specificity %           
  --------------------------------------- ------ -------------------- --------------- --------------- ------- -------
  Cho *et al* \[[@ref33]\]                2006   141                  98.3            96.7            96.7    64.4
  Kotsianos-Hermle *et al* \[[@ref30]\]   2009   97                   96,5            97.5            923     88.5
  Shin *et al* \[[@ref25]\]               2011   55                   96              100             91,8    93
  Chang *et al* \[[@ref32]\]              2011   67                   92              //              63      //
  Wang *et al* ^19^                       2012   213                  95.3            90.6            80.5    82.5
  Lin *et al* \[[@ref21]\]                2012   81                   100             95              100     85
  Wang *et al* \[[@ref20]\]               2012   155                  96.1            93.2            91.9    88,7
  Chen *et al* \[[@ref31]\]               2013   175                  92.5            88.1            86.2    87.5
  Kim *et al* \[[@ref22]\]                2013   38                   92              98              87.5    62.5
  Kim *et al* \[[@ref29]\]                2014   87                   89.2            98.7            79      80.1
  Jeh *et al* \[[@ref23]\]                2016   173                  88              95.7            76.2    49.4
  Schmachtenberg *et al* \[[@ref44]\]     2017   28                   93.3            100             83.3    83.3
  Niu *et al* \[[@ref24]\]                2019   398                  92.23           82.52           77.62   80.24

###### Studies in which the detection rate of ABUS (Automatic Breast Ultrasound) is significantly better of US (hand held ultrasound) in clinical practice.

  Author                       Year   Number of patients   Detection %   
  ---------------------------- ------ -------------------- ------------- ------
  Zhang *et al* \[[@ref26]\]   2012   82                   89.9          60.6
  Xiao *et al* \[[@ref27]\]    2015   300                  100           78.2
